- March 13, 2010
- 08:29 PM CET
- search
- Disclaimer
- PRIVACY POLICY
- Imprint
- RSS
- ©2010 EVOTEC
- Loading...
Archive
Evotec Achieves Milestone in Medicinal Chemistry Collaboration with Ono Pharmaceutical Co., Ltd.
14 December 2009
- Evotec receives milestone from Ono for the progression of novel protease inhibitors into lead optimisation - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) today announced that it has...
Evotec to Voluntarily Delist from NASDAQ
Evotec Receives a EUR 2.5 Million Milestone Payment in its Research Collaboration with Boehringer Ingelheim
Evotec Signs Agreement with DiscoveRx Corporation to Support High Throughput Screening Services
Hamburg, Germany / Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC), a leading provider in the discovery and development of novel small molecule drugs and DiscoveRx Corporation (Fremont, USA), a premier provider of innovative c...
- read moreEvotec Extends Medicinal Chemistry Collaboration with Ono Pharmaceutical Co., Ltd.
- Evotec extends its research collaboration with Ono to include an ion channel target - Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) today announced that it has extended its current research collaboration with ...
- read moreEvotec achieves milestone with Cardioxyl Pharmaceuticals - as compound enters the clinic
Evotec announces Research Agreement
with Biogen Idec
Evotec will use its expertise and capabilities in compound screening to identify hit compounds
Hamburg, Germany / Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC), a leading provider in the discovery and development of novel small molecule drugs, today announced that it has entered into a research agreement with Biogen Idec (NASDAQ: BIIB), a leading biopharmaceutical company headquartered in Cambridge, Mass., USA.
Evotec starts Phase I with EVT 103, an NR2B-selective NMDA receptor antagonist
Evotec completes acquisition of controlling majority stake in Research Support International Private Limited (RSIPL)
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) announced today that the acquisition of the controlling majority stake of Research Support International Private Limited ("RSIPL") has been successfully completed and that RSIPL is a 70%, majority owned subsidiary of Evotec as of August 31, 2009.
- read more